These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 7370952)

  • 1. Immunocompetence, immunosuppression, and human breast cancer. II. Further evidence of initial immune impairment by integrated assessment effect of nodal involvement (N) and of primary tumor size (T).
    Adler A; Stein JA; Ben-Efraim S
    Cancer; 1980 Apr; 45(8):2061-73. PubMed ID: 7370952
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunocompetence, immunosuppression, and human breast cancer. III. Prognostic significance of initial level of immunocompetence in early and advanced disease.
    Adler A; Stein JA; Ben-Efraim S
    Cancer; 1980 Apr; 45(8):2074-83. PubMed ID: 7370953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunocompetence, immunosuppression, and human breast cancer. I. An analysis of their relationship by known parameters of cell-mediated immunity in well-defined clinical stages of disease.
    Stein JA; Adler A; Efraim SB; Maor M
    Cancer; 1976 Sep; 38(3):1171-87. PubMed ID: 953963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biological markers and breast cancer. A multiparametric study. II. Depressed immune competence.
    Mandeville R; Lamoureux G; Legault-Poisson S; Poisson R
    Cancer; 1982 Oct; 50(7):1280-8. PubMed ID: 6980699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multiparametric observation of immune competence in breast cancer and its correlation with tumour load and prognosis.
    Das SN; Khanna NN; Khanna S
    Ann Acad Med Singap; 1985 Apr; 14(2):374-81. PubMed ID: 3876055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNCB and PPD skin testing in breast cancer.
    Munzarová M; Kovarík J; Ninger E; Zemanová D; Lauerová L; Kolcová V; Hlávková J; Pacovský Z
    Neoplasma; 1983; 30(4):385-9. PubMed ID: 6888607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunobiology of operable breast cancer: an assessment of biologic risk by immunoparameters.
    Wanebo HJ; Rosen PP; Thaler T; Urban JA; Oettgen HF
    Ann Surg; 1976 Sep; 184(3):258-67. PubMed ID: 962394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Cellular immunity indices in benign breast tumors].
    Baisheva SA; Zhalgasbaeva GT; Kaliev IuSh; Mezinova NN
    Vopr Onkol; 1980; 26(5):15-9. PubMed ID: 7385708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of lymphocyte immunity in breast cancer patients.
    Head JF; Elliott RL; McCoy JL
    Breast Cancer Res Treat; 1993; 26(1):77-88. PubMed ID: 8400326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNCB and PPD skin tests and prognosis in 152 patients with breast cancer. A prospective 2-year follow-up.
    Munzarová M; Kovarík J; Hlávková J; Popelínský L; Lauerová L
    Neoplasma; 1985; 32(1):45-50. PubMed ID: 3982560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Intact cellular immune response in patients with locally metastasizing breast carcinoma at the time of diagnosis].
    Ludwig C; Hartmann D; Landmann R; Wesp M; Rosenfelder G; Stucki D; Buser M; Obrecht JP
    Schweiz Med Wochenschr; 1983 Dec; 113(50):1908-11. PubMed ID: 6229873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced mitogenic stimulation of peripheral blood mononuclear cells as a prognostic parameter for the course of breast cancer: a prospective longitudinal study.
    Wiltschke C; Krainer M; Budinsky AC; Berger A; Müller C; Zeillinger R; Speiser P; Kubista E; Eibl M; Zielinski CC
    Br J Cancer; 1995 Jun; 71(6):1292-6. PubMed ID: 7779726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assays of immunocompetence in the staging and prognosis of cancer.
    Robinson JC
    Surg Gynecol Obstet; 1981 Dec; 153(6):909-21. PubMed ID: 7029761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum glycoproteins in cancer patients: first report of correlations with in vitro and in vivo parameters of cellular immunity.
    Baskies AM; Chretien PB; Weiss JF; Makuch RW; Beveridge RA; Catalona WJ; Spiegel HE
    Cancer; 1980 Jun; 45(12):3050-60. PubMed ID: 7388749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Variations in functional immunocompetence of individual tumor-draining lymph nodes in humans.
    Hoon DS; Korn EL; Cochran AJ
    Cancer Res; 1987 Mar; 47(6):1740-4. PubMed ID: 3493068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunodeficiency in different histotypes of radically operable gastrointestinal cancers.
    Romano F; Uggeri F; Crippa S; Di Stefano G; Scotti M; Scaini A; Caprotti R; Uggeri F
    J Exp Clin Cancer Res; 2004 Jun; 23(2):195-200. PubMed ID: 15354402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Percent positive axillary lymph node metastasis predicts survival in patients with non-metastatic breast cancer.
    Lale Atahan I; Yildiz F; Ozyigit G; Sari S; Gurkaynak M; Selek U; Hayran M
    Acta Oncol; 2008; 47(2):232-8. PubMed ID: 17924207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer.
    Gajdos C; Tartter PI; Estabrook A; Gistrak MA; Jaffer S; Bleiweiss IJ
    J Surg Oncol; 2002 May; 80(1):4-11. PubMed ID: 11967899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunocompetence and its modification after BCG immunotherapy in patients with colon carcinoma.
    Pacheco-Rupil B; Depiante M; Yantorno C; Nuñez P; Casadio B
    Acta Gastroenterol Latinoam; 1980; 10(4):277-82. PubMed ID: 7270013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lymphocyte response to PHA and patient response to chemotherapy in breast cancer.
    Jones KD; Whitehead RH; Grimshaw D; Hughes LE
    Clin Oncol; 1980 Jun; 6(2):159-66. PubMed ID: 7408283
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.